Suzetrigine (a NaV1.8 inhibitor) versus placebo for acute postoperative pain: A systematic review and meta-analysis of randomized controlled trials.

Key Points

• This review aims to evaluate the efficacy of suzetrigine compared to placebo for managing acute postoperative pain.
• Performed a systematic review of randomized controlled trials
• Compared outcomes of suzetrigine and placebo groups
• Analyzed pain levels at 24 to 48 hours post-surgery
• Suzetrigine resulted in modest reductions in pain compared to placebo
• Opioid consumption data were inconsistently reported, limiting conclusions on opioid-sparing effects

Abstract